Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has increased the capacity of its UK facilities. The expansion has been driven by client demand and coincides with the establishment of an expanded panel of immuno-oncology services at Crown Bioscience’s European base, including bioluminescent imaging of popular syngeneic cell line models. “This is yet another example of Crown Bios...